###begin article-title 0
Novel pathogenic mutations and skin biopsy analysis in Knobloch syndrome
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
To facilitate future diagnosis of Knobloch syndrome (KS) and better understand its etiology, we sought to identify not yet described COL18A1 mutations in KS patients. In addition, we tested whether mutations in this gene lead to absence of the COL18A1 gene product and attempted to better characterize the functional effect of a previously reported missense mutation.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
Direct sequencing of COL18A1 exons was performed in KS patients from four unrelated pedigrees. We used immunofluorescent histochemistry in skin biopsies to evaluate the presence of type XVIII collagen in four KS patients carrying two already described mutations: c.3277C>T, a nonsense mutation, and c.3601G>A, a missense mutation. Furthermore, we determined the binding properties of the mutated endostatin domain p.A1381T (c.3601G>A) to extracellular matrix proteins using ELISA and surface plasmon resonance assays.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
We identified four novel mutations in COL18A1, including a large deletion involving exon 41. Skin biopsies from KS patients revealed lack of type XVIII collagen in epithelial basement membranes and blood vessels. We also found a reduced affinity of p.A1381T endostatin to some extracellular matrix components.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
COL18A1 mutations involved in Knobloch syndrome have a distribution bias toward the coding exons of the C-terminal end. Large deletions must also be considered when point mutations are not identified in patients with characteristic KS phenotype. We report, for the first time, lack of type XVIII collagen in KS patients by immunofluorescent histochemistry in skin biopsy samples. As a final point, we suggest the employment of this technique as a preliminary and complementary test for diagnosis of KS in cases when mutation screening either does not detect mutations or reveals mutations of uncertain effect, such as the p.A1381T change.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 377 384 377 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1043 1044 1043 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 1270 1271 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 1272 1273 1272 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1274 1275 1274 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1497 1498 1497 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1499 1501 1499 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1669 1671 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1672 1674 1672 1674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
Knobloch syndrome (KS; OMIM ) is an autosomal recessive disorder characterized by high myopia, macular abnormalities, vitreoretinal degeneration, retinal detachment, and occipital encephalocele [1-4]. The spectrum of clinical variability is not completely known due to the small number of cases reported in the literature [5]. Most KS cases are caused by null mutations in the COL18A1 gene (chr21q22.3), which comprises 43 exons and transcribes three different isoforms by the use of two promoters and alternative splicing in the third exon [4,6]. The three encoded collagen XVIII proteins differ only by their signal peptides and by part of the N-terminal region of the NC11 domain. The short isoform (NC11-303) is transcribed from the first promoter, upstream of exon 1, and is encoded by exons 1, 2, 4-43. The intermediate (NC11-493) and long (NC11-728) forms are transcribed from the second promoter, upstream of exon 3, and they differ by use of an internal splice site within exon 3. Collagen XVIII is a component of basement membranes [7]; however, the abundance of its isoforms varies: the short isoform is predominant in most tissues, including heart, kidney, retina, and fetal brain, while the intermediate and long isoforms are highly expressed in the liver [3,4,6]. The C-terminal domain of type XVIII collagen can be cleaved to form endostatin, which functions as a potent angiogenesis inhibitor that influences endothelial cell proliferation, migration, apoptosis and tubulogenesis [8-11]. Endostatin binds to several extracellular matrix (ECM) components, including laminin-1, fibulin-1, fibulin-2, nidogen-2, perlecan, heparan sulfate, and fibronectin [12-14].
###end p 11
###begin p 12
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 471 478 471 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 812 819 812 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
To date, 12 rare mutations have been described in KS patients with the typical clinical features of the disease [3-5,15-17]. All mutations, with the exception of a missense change (p.A1381T; numbered according to GenBank cDNA ) of still unclear functional effect on the protein [18,19], are predicted to create premature stop codons. These mutations possibly lead to a lack of the protein, even though the complete lack of collagen XVIII has still not been demonstrated. COL18A1 mutations are distributed along the gene in regions common to all known isoforms, except for c.12-2A>T, which only affects the short isoform. The description of pathogenic mutations in a larger number of KS patients and further functional analysis of the mutation p.A1381T may better characterize the spectrum of mutations along the COL18A1 gene.
###end p 12
###begin p 13
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
Screening the entire gene for mutations is still time consuming. We have previously shown that endostatin plasma measurements do not allow a precise diagnosis, as patients with null mutations had positive levels of this fragment [4], and no other methods to confirm KS diagnosis were tested. New strategies that might allow the screening of a larger number of patients, including those without the full phenotype of the syndrome, could help delineate the clinical variability.
###end p 13
###begin p 14
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
In the present work we describe four new families with KS patients and the respective responsible mutations in COL18A1. Consistent with previous results, we find heterogeneity for mutation sites leading to this syndrome. We also assessed the immunohistochemical expression of type XVIII collagen in skin biopsies of KS patients carrying nonsense mutations to test the potential of this method as a screening tool for a larger number of patients. Finally, we evaluated in situ and in vitro effects of endostatin p.A1381T by testing skin biopsies for the presence of type XVIII collagen in KS patients carrying this mutation and evaluating the binding properties of the mutated endostatin to other ECM components.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
COL18A1 mutations analysis
###end title 16
###begin p 17
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Five KS patients were referred to the Centro de Estudos do Genoma Humano at the University of Sao Paulo. Two were siblings and the other three were not related. They presented with typical KS phenotypic characteristics: high myopia detected early in childhood (usually before 1 year of age) and occipital encephalocele, as described elsewhere [2,20]. No other alterations were observed.
###end p 17
###begin p 18
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
We screened for mutations in the COL18A1 gene by direct sequencing of exons and flanking intronic regions, as previously described [4]. All mutations were named according to the nomenclature suggested by den Dunnen and Antonarakis [21]. The numbering followed the short isoform (GenBank ), except where indicated.
###end p 18
###begin title 19
Skin biopsies
###end title 19
###begin p 20
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 238 244 <span type="species:ncbi:8164">Suzuki</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
After informed consent was obtained, 5 mm skin punch biopsies were taken from the forearms of four other KS patients, who were from two unrelated families. Clinical and molecular analysis of these patients has been described in detail by Suzuki et al. and Kliemann et al. [4,18]. Control skin samples were obtained from two patients that were undergoing surgery and had no suspicion of KS. Informed consent was also obtained from these patients. This project was approved by the Ethical Committee of the Institute of Biosciences, University of Sao Paulo (Sao Paulo, Brazil).
###end p 20
###begin p 21
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
Tissue samples were fixed according to a procedure described elsewhere [22]. Briefly, samples were immediately fixed and cryosubstituted in a -70 degreesC solution of 80% methanol and 20% dimethyl sulfoxide for 5-7 days, transferred to -20 degreesC for 1-2 days, and then brought to room temperature. Samples were rinsed 3X in absolute ethanol and embedded in Paraplast Plus following standard protocols. In addition to maintaining morphological structure, this method also appears to preserve the antigenicity to a higher degree than aldehyde fixatives.
###end p 21
###begin title 22
Immunofluorescent histochemistry
###end title 22
###begin p 23
###xml 179 180 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 183 184 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 193 194 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 196 197 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 731 733 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 594 600 <span type="species:ncbi:9986">rabbit</span>
###xml 768 774 <span type="species:ncbi:9986">Rabbit</span>
###xml 780 785 <span type="species:ncbi:9606">human</span>
###xml 1067 1071 <span type="species:ncbi:9925">goat</span>
###xml 1077 1083 <span type="species:ncbi:9986">rabbit</span>
Xylene was used to dewax 7 mum-thick sections. These were then rehydrated through a graded series of ethanol into phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). Next, 1 mg/ml testicular hyaluronidase (Sigma, St. Louis, MO) in 50 mM acetate buffer, pH 5, was added at room temperature for 30 min. This was followed by several washes in PBS. Blocking was achieved using 2% BSA (BSA) in PBS at room temperature for 1 h followed by an overnight incubation at 4 degreesC with primary antibodies diluted in PBS containing 0.1% BSA and 0.01% Tween-20. A rabbit polyclonal antibody against type XVIII collagen (QH48.18, "anti-all") which recognizes all three isoforms of type XVIII collagen [23] was used at a dilution of 1:300. Rabbit anti-human type IV collagen polyclonal antibody (Rockland, Gilbertsville, PA), an antibody against type IV collagen, was diluted 1:400 before it was used as a basement membrane marker. After several rinses in PBS, sections were incubated for 1 h at room temperature with 1:300 Cy3-conjugated goat anti-rabbit IgG secondary antibody (Jackson Laboratory, Bar Harbor, ME). After several rinses in PBS, sections were mounted in a mixture of 10% 1.0 M Tris-HCl, pH 9.0 and 90% glycerol and analyzed using a laser scanning confocal microscope (Zeiss 510META; Carl Zeiss AG, Oberkochen, Germany).
###end p 23
###begin p 24
The distribution patterns and levels of expression of types IV and XVIII collagens were analyzed using pseudocolor images made with the thermo lookup table in the Confocal . This tool utilizes gray-scale pixel values to generate pseudocolor images that allow the discrimination of small differences in the level of immunofluorescence.
###end p 24
###begin title 25
Molecular modeling
###end title 25
###begin p 26
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human endostatin structure (1BNL) was obtained from the . the p.A1381T change was created and analyzed using GRASP [24] and Insight-II/Discover software (Molecular Simulations Inc., San Diego, CA).
###end p 26
###begin title 27
Recombinant endostatin production
###end title 27
###begin p 28
The coding region of the endostatin domain was cloned into the pET-15b vector (Novagen, Madison, WI). p.A1381T endostatin was produced by PCR-based site directed mutagenesis.
###end p 28
###begin p 29
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 143 150 143 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 143 150 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1124 1129 <span type="species:ncbi:9606">Human</span>
Endostatin production and purification were based on a procedure published elsewhere [25]. Briefly, recombinant human endostatin expression in E. coli was induced using 1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) for 3 h. Cells were isolated by centrifugation and lysed by freeze thaw cycle in GUMCAC-0-buffer, which contained 6 M guanidine-HCl, 0.5 M NaCl, and 20 mM Tris-HCl, pH 7.9. This was followed by sonication in the presence of 15 mM beta-mercaptoethanol. Lysate was loaded onto a ProBondtrade mark column (Invitrogen, Carlsbad, CA) that had been previously equilibrated with URMCAC-0 buffer, which contained 8 M urea, 0.5 NaCl, and 20 mM Tris-HCl, pH 7.9. Endostatin was eluted with a gradient concentration of imidazole (0 to 500 mM) and dialyzed against 4 M urea, 0.1 M NaCl, 1 mM reduced glutathione, 0.1 mM oxidized glutathione, 20 mM Tris-HCl pH 7.9 (16 h at 4 degreesC). This was followed by a dialysis against 1 M urea, 0.1 M NaCl, 0.1 mM reduced glutathione, 0.01 mM oxidized glutathione, 20 mM Tris-HCl pH 7.9 (6 h at 4 degreesC), and a final dialysis step against PBS pH 6.9 (16 h at 4 degreesC). Human endostatin was then loaded onto a HiTrap-SP column (Amersham Biosciences, Uppsala, Sweden) and eluted using a NaCl gradient (0 to 1.5 M) in PBS pH 6.9. Buffer was exchanged by dialysis against 0.1 M NaCl and 20 mM Tris-HCl (pH 7.4) for 16 h at 4 degreesC.
###end p 29
###begin title 30
Binding assays
###end title 30
###begin p 31
###xml 280 282 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 396 398 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 517 519 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 285 290 <span type="species:ncbi:10090">Mouse</span>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
Surface plasmon resonance (SPR) assays were performed with a BIAcore(R) 3000 instrument (Biacore AB, Uppsala, Sweden). Extracellular matrix proteins, the laminin-1-nidogen-1 complex, perlecan, and fibulin were immobilized on CM5 sensor chips (Biacore AB) as described previously [26]. Mouse laminin-1-nidogen-1 complex and mouse perlecan were prepared from the mouse Engelbreth-Holm-Swarm tumor [27]. The recombinant microfibrillar component fibulin-1 was prepared following the procedure published by Sasaki et al. [28]. Binding assays were performed in triplicates in 0.02 M Tris-HCl, 0.11 M NaCl containing 0.05% P-20 surfactant (Biacore AB) at a flow rate of 20 mul/min. The association phase was monitored for 3 min, and the dissociation curve was recorded for 10 min. The bulk effects were subtracted using the reference control surfaces. The chips were regenerated by treatment with 1 M NaCl for 30 s. For the calculation of kinetics constants, the sensorgrams at concentrations of 0, 10, 50, 200, and 400 nM were fitted globally to the 1:1 Langmuir model with BIAevaluation software version 3.1.
###end p 31
###begin p 32
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 366 367 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 378 379 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 667 669 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 962 963 952 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 964 965 954 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 642 647 <span type="species:ncbi:9606">human</span>
###xml 814 825 <span type="species:ncbi:3704">horseradish</span>
ELISA assays were based on a procedure used by Rehn et al. [25]. Laminin, type IV collagen, nidogen-1, fibulin-1, and 10 microg/ml heparin-BSA were coated onto the surface of microtiter wells at 4 degreesC overnight. All the other steps were performed at room temperature. The wells were blocked with 5% nonfat milk in 0.05 M Tris-HCl, pH 7.4, 0.11 M NaCl, 2 mM CaCl2, 1 mM MgCl2 (TBS-Ca/Mg) for 1 h and then washed with 0.05% Tween-20 in TBS-Ca/Mg, and incubated for 3 h with endostatin as a soluble ligand diluted in 5% nonfat milk TBS-Ca/Mg. After thoroughly washing, the samples were incubated for 1 h with the antibody HES.6 against the human endostatin domain [29] diluted in TBS-Ca/Mg-5% milk, followed by washing with 0.05% Tween-20 in TBS-Ca/Mg, and incubation with the secondary antibody conjugated with horseradish peroxidase. Endostatin bound to the immobilized proteins was detected by adding 5-aminosalicylic acid (Sigma) in the presence of 0.01% H2O2. Detection was performed at 490 nm.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
Identification of new mutations in COL18A1 leading to KS
###end title 34
###begin p 35
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Mutation screening of the COL18A1 gene was performed in five KS patients, who were from four unrelated families (KS14-17). All the patients presented with congenital high myopia and occipital encephalocele, typical KS phenotypic characteristics. Three of the families are Brazilian (KS14, KS16, and KS17) and one is North American (KS15).
###end p 35
###begin p 36
###xml 232 239 232 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 1304 1311 1304 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 635 642 <span type="species:ncbi:9606">patient</span>
###xml 891 898 <span type="species:ncbi:9606">patient</span>
###xml 1187 1194 <span type="species:ncbi:9606">patient</span>
We identified four mutations not previously described: one insertion, two out-of-frame deletions in exons coding the C-terminal region of the protein, and a splice site mutation. All of these possibly lead to premature stop codons (Table 1). The mutation that occurs at the acceptor splice site of intron 7, c.929-2A>G, involves a highly conserved base and is predicted to disrupt splicing according to computational analysis (NetGene2 version 2.4 [30]; NNSPLICE version 0.9 [31]). We have detected a mutation in only one of the alleles in families KS14 and KS15, and these patients may be compound heterozygotes. Even though the KS16 patient was initially identified as a homozygous carrier of the mutation c.3514_3515delCT, we found only her mother harbors this mutation. Paternity was confirmed with the analysis of five microsatellite markers (D22S944, S1623, S1638, S1648, S1709). This patient also appeared homozygous for another mutation in this exon (c.3570G>A), which is present in the mother in heterozygosity but it is not present in the father, who carries only the G allele of this SNP. Therefore, we concluded that the father carries a deletion of at least exon 41 and the patient is actually hemizygous for the c.3514_3515delCT mutation and is a compound heterozygote for mutations in the COL18A1 gene.
###end p 36
###begin title 37
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Mutations identified in KS patients.
###end title 37
###begin p 38
###xml 68 76 <span type="species:ncbi:9606">patients</span>
List of published COL18A1 mutations identified in Knobloch syndrome patients and the exon numbers of the mutation sites. Asterisk represents position based on the NC11-493 isoform ().
###end p 38
###begin title 39
p.A1381T mutation leads to a weaker binding affinity to some of the ECM proteins
###end title 39
###begin p 40
###xml 353 361 353 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 667 675 667 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 677 684 677 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
To better understand if the rare p.A1381T endostatin mutation has the potential to disrupt its function, we performed ELISA and SPR assays to evaluate the fragment's ability to bind to other ECM proteins. Our molecular modeling analysis of the p.A1381T endostatin suggested that it was possible to accommodate the threonine side chain in this position (Figure 1). ELISA assays showed the binding properties of the p.A1381T endostatin to be similar to the wild type endostatin, without any significant differences between them. SPR experiments showed that the p.A1381T mutation leads to a somewhat weaker binding affinity to some of the ECM proteins that were tested (Figure 2; Table 2). The differences between wild type and mutant endostatin binding to laminin-1-nidogen-1 complex and to fibulin-1 were small but significant (p=0.0017 and p=0.0011, respectively). Perlecan binding was weak for both p.A1381T and wild type endostatins and the difference was not significant.
###end p 40
###begin p 41
###xml 110 111 110 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 127 128 127 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Molecular modeling of wild type and p.A1381T endostatins. Analysis of the electrostatic surface of wild type (A) and p.A1381T (B) endostatins. Areas shown in red represent a negative potential while the blue areas are positive. The position 48 of the endostatin domain (Protein Data Bank entry 1BNL) corresponds to the position 1381 of the NC11-493 isoform ().
###end p 41
###begin p 42
###xml 293 294 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 299 300 299 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 321 322 321 322 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 327 328 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 354 355 354 355 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 360 361 360 361 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
SPR sensorgrams of endostatin interactions with ECM components. Endostatin variants (wild type, mutant p.A1381T) were diluted to a concentration series in 0.02 M Tris-HCl, 0.11 M NaCl containing 0.05% P-20, and then injected into the sensor chips immobilized with laminin-1-nidogen-1 complex (A=wt, B=p.A1381T), fibulin (C=wt, D=p.A1381T), and perlecan (E=wt, F=p.A1381T) at 25 degreesC with a flow rate of 20 mul/min. Sensorgrams show binding of various concentrations of endostatin to the coated sensor surfaces. The association curves were monitored for 3 min, and the dissociation phases were recorded for 10 min but presented for 5 min. All the kinetics studies were performed three times independently at concentrations of 0-400 nM, and the data were analyzed with BIAevaluation software version 3.1 using the 1:1 Langmuir binding model.
###end p 42
###begin title 43
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
Binding affinities (KD) of wild type and mutant endostatins to ECM components
###end title 43
###begin p 44
The kinetics constants were obtained by fitting the sensorgrams to the 1:1 Langmuir model.
###end p 44
###begin title 45
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Skin biopsies from KS patients do not show COL18A1 expression
###end title 45
###begin p 46
###xml 670 678 670 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 1063 1071 1063 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
Null mutations that affect all type XVIII collagen isoforms must lead to complete lack of the protein. To confirm the absence of type XVIII collagen and to evaluate the possibility of distinguishing KS patients from normal individuals by the analysis of type XVIII collagen in skin biopsies, we performed fluorescent immunohistochemical staining for type XVIII collagen in skin biopsies from two KS individuals carrying the previously described nonsense mutation c.3277C>T. We observed a complete lack of type XVIII collagen expression in the tissue sections, while control samples displayed high levels of staining in the epithelial and endothelial basement membranes (Figure 3). The lack of expression of type XVIII collagen was especially evident in pseudocolor, thermo images in which even minor amounts of immunofluorescently labeled material can be visualized. Although another basement membrane protein, type IV collagen, showed a similar distribution pattern in both control and KS groups, its immunostaining intensity in KS samples was noticeably lower (Figure 3).
###end p 46
###begin p 47
###xml 135 142 135 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, F, K</bold>
###xml 397 401 397 401 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B, C</bold>
###xml 478 482 478 482 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G, H</bold>
###xml 556 560 556 560 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L, M</bold>
###xml 660 661 660 661 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 695 699 695 699 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C, H</bold>
###xml 785 789 785 789 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N, O</bold>
###xml 800 810 800 810 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D, E, I, J</bold>
###xml 928 929 928 929 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
Immunofluorescent localization of type XVIII collagen in KS and control skin samples. Differential interference contrast (DIC) images (A, F, K) show that the epithelial and connective tissues obtained from skin biopsies were intact and well preserved after being prepared using cryofixation and cryosubstitution techniques. Immunolocalization analyses of KS patients carrying the p.A1381T change (B, C) and the nonsense mutation c.3277C>T (NC11-493 isoform position p.G1273X, ; G, H) were negative for expression of collagen XVIII as compared to controls (L, M). Pseudocolor, thermo images showed that collagen XVIII expression was present in control samples (M) but undetectable in KS samples (C, H). Although the distribution pattern of type IV collagen was similar in both control (N, O), and KS (D, E, I, J) groups, the immunostaining intensity was noticeably lower in KS samples. The thermo color bar to the right of panel E indicates immunofluorescence staining intensity: red, higher levels; blue/black, lower levels. Arrows point to basement membrane, and arrowheads mark blood vessels. Scale bars equal 100 mum.
###end p 47
###begin p 48
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
To understand the cause of KS in individuals carrying the change p.A1381T we also performed immunohistochemistry from skin biopsies of two patients. Surprisingly, they also showed lack of type XVIII collagen staining (Figure 3).
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 166 173 166 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 404 411 404 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 574 581 574 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 663 670 663 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 968 975 968 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
###xml 1350 1358 <span type="species:ncbi:9606">patients</span>
KS is thought to be a rare condition: only 42 patients from 15 unrelated families have been described [2,4,5,16-18,20,32-36]. Among these families, only 12 different COL18A1 mutations have been identified [3-5,15-17]. Although some clustering has been observed in exon 41, there is heterogeneity of mutation site distribution. Here we describe four unrelated families harboring five different mutations (Table 1); all of the patients are compound heterozygotes. KS16 represents an unusual case, where the chromosome inherited from the father has an undetermined deletion in COL18A1 that includes exon 41. This mechanism may elucidate cases already reported where COL18A1 mutations were not detected [4]. Sequencing the 43 exons of this gene is laborious for small study centers to confirm the KS diagnosis, so the identification of biases in mutation distribution could help in the molecular diagnosis. Mutations identified so far indicate that exons 30 through 42 of COL18A1 are more frequently mutated, as 5 (83.3%) out of 6 mutations here identified were located in these exons, as well as 9 (64.3%) out of 14 previously identified mutations. Interestingly, 5 (26.3%) out of 19 mutations previously identified are located in exon 41, pointing to this exon as the most frequently affected. For this reason, we suggest that mutation screening in KS patients should start with these exons. It is possible that KS is less rare, and the spectrum of clinical variability is wider than predicted.
###end p 50
###begin p 51
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
To find an additional way to detect type XVIII collagen disruption in KS patients and gain a deeper understanding of the KS etiology, we performed protein measurements in situ and characterization of a mutation with an unknown effect in vitro. We evaluated for the first time the immunohistochemical presence of type XVIII collagen in KS patients. We have analyzed the distribution pattern of type XVIII collagen in skin biopsies of four KS patients: two siblings with the known pathogenic nonsense mutation c.3277C>T and two other siblings with the missense endostatin mutation c.3601G>A (p.A1381T). As expected for carriers of null mutations, we were unable to detect type XVIII collagen in any of the tested KS patients, including those with typical KS clinical features that harbor the mutation p.A1381T, of uncertain effect, confirming that the primary molecular defect is in collagen XVIII. Interestingly, the KS samples also show a lower expression level of type IV collagen when compared with the control samples. Since endostatin/collagen XVIII binds to several ECM components [12-14], it is possible that a lack of this protein may lead to changes in the overall organization and stability of the ECM, especially in the basement membrane where it is normally expressed.
###end p 51
###begin p 52
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 1292 1300 1292 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1.</italic>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
We also tested the p.A1381T endostatin for binding affinity to a selection of ECM proteins. Even though the molecular modeling of the protein did not predict a significant modification, p.A1381T has a weaker affinity to some of the tested ECM components when compared with wild-type endostatin. Indeed, Stahl et al. (2005) [19] used a recombinant human p.A1381T endostatin in a mammalian expression system and suggested that this change leads to a reduced folding efficiency. They based this suggestion on the residue position and the observed 40% reduction in p.A1381T endostatin production. Considering that KS is probably caused by a complete disruption of at least the isoform NC11-303, the current data does not allow us to conclude that the p.A1381T residue change is sufficient to lead to the KS phenotype or is pathogenic, but this hypothesis seems unlikely. Although in silico analysis indicates that the c.3601G>A change does not create new splice sites (data not shown), we cannot exclude the possibility that it affects splicing in vivo and leads to creation of a premature stop codon, since no type XVIII collagen was detected in the skin biopsies of these patients. It is also possible that the KS in this family is caused by a yet to be detected mutation or larger deletion in COL18A1.
###end p 52
###begin p 53
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 566 573 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 802 809 802 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 1290 1298 <span type="species:ncbi:9606">patients</span>
We have previously shown that endostatin serum levels measured by an ELISA assay were lower in KS patients as compared with controls [4]. Although we were able to discriminate patients and controls through this method, we raised the hypothesis that the antibody used in the assay is cross-reactive. This is evidenced by the positive endostatin levels in KS patients that are carriers of null mutations, which should lead to a complete or nearly complete lack of type XVIII collagen. The immunohistochemistry results confirm our prediction that null mutations in the COL18A1 gene lead to a severe depletion of the protein. Therefore, immunohistochemical assessment of type XVIII collagen for diagnosing KS may be more precise than endostatin measurements through ELISA assays. The mutation screening of COL18A1 gene is still expensive and laborious, and the effect of some detected mutations may be uncertain, as is the case for the endostatin p.A1381T change. Even when a possible pathogenic mutation is found, the immunohistochemical analysis of skin biopsies can be an important tool to confirm the diagnosis. Finally, we show for the first time that it is possible to diagnose KS through the direct detection of the protein. In turn, this could allow the screening of a larger number of patients with a possible diagnosis of KS and could help in understanding the phenotypic spectrum of this syndrome.
###end p 53
###begin title 54
Acknowledgments
###end title 54
###begin p 55
###xml 330 337 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
We thank Paivi Pirila for her assistance on the SPR assays, Dr. Luis Eduardo Soares Netto and his students for the help with endostatin expression, Mrs. Juliana F. Lucatelli for help in sequencing analysis, Daniela Hipolito Carvalho for help with the preparation of samples for immunohistochemistry, Bjorn Olsen for providing the COL18A1 cDNA plasmid, and Dr. Shannon Fisher for proofreading the manuscript. This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - CEPID, and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
###end p 55
###begin title 56
References
###end title 56
###begin article-title 57
Syndromes with cephaloceles.
###end article-title 57
###begin article-title 58
Knobloch syndrome in a large Brazilian consanguineous family: confirmation of autosomal recessive inheritance.
###end article-title 58
###begin article-title 59
Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome).
###end article-title 59
###begin article-title 60
Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome.
###end article-title 60
###begin article-title 61
###xml 54 59 <span type="species:ncbi:9606">human</span>
Mutations in collagen 18A1 and their relevance to the human phenotype.
###end article-title 61
###begin article-title 62
###xml 51 56 <span type="species:ncbi:9606">human</span>
Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts.
###end article-title 62
###begin article-title 63
Collagen XVIII is a basement membrane heparan sulfate proteoglycan.
###end article-title 63
###begin article-title 64
Endostatin induces endothelial cell apoptosis.
###end article-title 64
###begin article-title 65
Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes.
###end article-title 65
###begin article-title 66
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
###end article-title 66
###begin article-title 67
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
###end article-title 67
###begin article-title 68
Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution.
###end article-title 68
###begin article-title 69
Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin.
###end article-title 69
###begin article-title 70
Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity.
###end article-title 70
###begin article-title 71
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity, and a functionally impaired polymorphism in endostatin.
###end article-title 71
###begin article-title 72
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL18A1</italic>
CNS malformations in Knobloch syndrome with splice mutation in COL18A1 gene.
###end article-title 72
###begin article-title 73
A phenotypic variant of Knobloch syndrome.
###end article-title 73
###begin article-title 74
Evidence of neuronal migration disorders in Knobloch syndrome: clinical and molecular analysis of two novel families.
###end article-title 74
###begin article-title 75
Endostatin phenylalanines 31 and 34 define a receptor binding site.
###end article-title 75
###begin article-title 76
The second report of Knobloch syndrome.
###end article-title 76
###begin article-title 77
###xml 36 41 <span type="species:ncbi:9606">human</span>
Nomenclature for the description of human sequence variations.
###end article-title 77
###begin article-title 78
Collagen XVIII/endostatin is associated with the epithelial-mesenchymal transformation in the atrioventricular valves during cardiac development.
###end article-title 78
###begin article-title 79
###xml 143 149 <span type="species:ncbi:9606">humans</span>
The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans.
###end article-title 79
###begin article-title 80
Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.
###end article-title 80
###begin article-title 81
Interaction of endostatin with integrins implicated in angiogenesis.
###end article-title 81
###begin article-title 82
The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin.
###end article-title 82
###begin article-title 83
Basement membranes.
###end article-title 83
###begin article-title 84
Structural characterization of two variants of fibulin-1 that differ in nidogen affinity.
###end article-title 84
###begin article-title 85
###xml 60 65 <span type="species:ncbi:9606">human</span>
Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases.
###end article-title 85
###begin article-title 86
###xml 14 19 <span type="species:ncbi:9606">human</span>
Prediction of human mRNA donor and acceptor sites from the DNA sequence.
###end article-title 86
###begin article-title 87
Improved splice site detection in Genie.
###end article-title 87
###begin article-title 88
A dominantly inherited syndrome of hyaloideoretinal degeneration, cleft palate and maxillary hypoplasia (Cervenka syndrome).
###end article-title 88
###begin article-title 89
Congenital scalp defects and vitreoretinal degeneration: redefining the Knobloch syndrome.
###end article-title 89
###begin article-title 90
Report of two sibs with Knobloch syndrome (encephalocoele and viteroretinal degeneration) and other anomalies.
###end article-title 90
###begin article-title 91
Knobloch syndrome involving midline scalp defect of the frontal region.
###end article-title 91
###begin article-title 92
###xml 38 45 <span type="species:ncbi:9606">patient</span>
Persistence of fetal vasculature in a patient with Knobloch syndrome: potential role for endostatin in fetal vascular remodeling of the eye.
###end article-title 92

